In-process research and development acquired in a business combination is expensed, consistent with the accounting treatment of a firm's own R&D expenditures. credited to the Equity Investment account. recorded as indefinite-lived intangible assets, subject to amortization. recorded as an indefinite-lived intangible asset, and annually tested for impairment